Review



fasn inhibitor tvb 2640  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress fasn inhibitor tvb 2640
    Therapeutic targeting of KAT2B-low RCC with a FASN inhibitor (A-B) Representative images of IHC staining of FASN in RCC cohort and statistical analysis. (C) Representative images of IHC staining for FASN and KAT2B in RCC tissues with high and low KAT2B expression. (D) Scatter plot of the relationship among KAT2B expression and FASN expression in advanced RCC tumors (n = 53). (E) The cell viability of ACHN and Caki-1 cells after treated <t>with</t> <t>TVB-2640</t> (n = 4). (F) The cell viability of 786O and 769P cells after treated with TVB-2640 (n = 10). Proteins from three independent sites in RCC tissues were extracted to detect KAT2B expression. (H) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM). 15 organoids were randomly selected from each group for statistical analysis. (I) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM) (n = 15). (J) Representative images of two PDOs with different KAT2B expression after treatment with TVB-2640 (n = 10). (K) Representative images of PRO-1 staining of PDOs. (L-M) The cell viability of ACHN cells (L) and case 1 primary RCC cells (M) with KAT2B knockdown after treated with TVB-2640 (n = 4). (N-O) The picture (N) of xenograft using 786O cells with KAT2B knockdown after treated with TVB-2640, and tumor growth curve (n = 4). Data were analyzed by unpaired t test (B, H, I, J), one-way ANOVA (O) or two-way ANOVA (E, F, G, L, M).
    Fasn Inhibitor Tvb 2640, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fasn+inhibitor+tvb+2640/Denifanstat/pmc13131402-129-23-27
    Average 94 stars, based on 13 article reviews
    fasn inhibitor tvb 2640 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma"

    Article Title: Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma

    Journal: Journal of Advanced Research

    doi: 10.1016/j.jare.2025.08.007

    Therapeutic targeting of KAT2B-low RCC with a FASN inhibitor (A-B) Representative images of IHC staining of FASN in RCC cohort and statistical analysis. (C) Representative images of IHC staining for FASN and KAT2B in RCC tissues with high and low KAT2B expression. (D) Scatter plot of the relationship among KAT2B expression and FASN expression in advanced RCC tumors (n = 53). (E) The cell viability of ACHN and Caki-1 cells after treated with TVB-2640 (n = 4). (F) The cell viability of 786O and 769P cells after treated with TVB-2640 (n = 10). Proteins from three independent sites in RCC tissues were extracted to detect KAT2B expression. (H) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM). 15 organoids were randomly selected from each group for statistical analysis. (I) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM) (n = 15). (J) Representative images of two PDOs with different KAT2B expression after treatment with TVB-2640 (n = 10). (K) Representative images of PRO-1 staining of PDOs. (L-M) The cell viability of ACHN cells (L) and case 1 primary RCC cells (M) with KAT2B knockdown after treated with TVB-2640 (n = 4). (N-O) The picture (N) of xenograft using 786O cells with KAT2B knockdown after treated with TVB-2640, and tumor growth curve (n = 4). Data were analyzed by unpaired t test (B, H, I, J), one-way ANOVA (O) or two-way ANOVA (E, F, G, L, M).
    Figure Legend Snippet: Therapeutic targeting of KAT2B-low RCC with a FASN inhibitor (A-B) Representative images of IHC staining of FASN in RCC cohort and statistical analysis. (C) Representative images of IHC staining for FASN and KAT2B in RCC tissues with high and low KAT2B expression. (D) Scatter plot of the relationship among KAT2B expression and FASN expression in advanced RCC tumors (n = 53). (E) The cell viability of ACHN and Caki-1 cells after treated with TVB-2640 (n = 4). (F) The cell viability of 786O and 769P cells after treated with TVB-2640 (n = 10). Proteins from three independent sites in RCC tissues were extracted to detect KAT2B expression. (H) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM). 15 organoids were randomly selected from each group for statistical analysis. (I) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM) (n = 15). (J) Representative images of two PDOs with different KAT2B expression after treatment with TVB-2640 (n = 10). (K) Representative images of PRO-1 staining of PDOs. (L-M) The cell viability of ACHN cells (L) and case 1 primary RCC cells (M) with KAT2B knockdown after treated with TVB-2640 (n = 4). (N-O) The picture (N) of xenograft using 786O cells with KAT2B knockdown after treated with TVB-2640, and tumor growth curve (n = 4). Data were analyzed by unpaired t test (B, H, I, J), one-way ANOVA (O) or two-way ANOVA (E, F, G, L, M).

    Techniques Used: Immunohistochemistry, Expressing, Staining, Knockdown

    Related Articles

    Immunohistochemistry:

    Article Title: Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma
    Article Snippet: In vivo trials of TVB-2640 treatment, a total of 5 × 10 6 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice.In vivo trials of TVB-2640 treatment, a total of 5 × 10 6 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice.. Four days after inoculation, the mice were randomly divided into two groups and treated with either the vehicle (30 % PEG400) or the FASN inhibitor TVB-2640 (HY-112829, MCE, USA) (100 mg/kg) once daily by oral gavage for 3 consecutive weeks.. Measure tumor growth every six days with a digital caliper.Measure tumor growth every six days with a digital caliper.

    Article Title: Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma.
    Article Snippet: vivo trials of TVB-2640 treatment, a total of 5 × 106 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice. .. Four days after inoculation, the mice were randomly divided into two groups and treated with either the vehicle (30 % PEG400) or the FASN inhibitor TVB-2640 (HY112829, MCE, USA) (100 mg/kg) once daily by oral gavage for 3 consecutive weeks. .. Measure tumor growth every six days with a digital caliper.

    Expressing:

    Article Title: Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma
    Article Snippet: In vivo trials of TVB-2640 treatment, a total of 5 × 10 6 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice.In vivo trials of TVB-2640 treatment, a total of 5 × 10 6 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice.. Four days after inoculation, the mice were randomly divided into two groups and treated with either the vehicle (30 % PEG400) or the FASN inhibitor TVB-2640 (HY-112829, MCE, USA) (100 mg/kg) once daily by oral gavage for 3 consecutive weeks.. Measure tumor growth every six days with a digital caliper.Measure tumor growth every six days with a digital caliper.

    Article Title: Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma.
    Article Snippet: vivo trials of TVB-2640 treatment, a total of 5 × 106 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice. .. Four days after inoculation, the mice were randomly divided into two groups and treated with either the vehicle (30 % PEG400) or the FASN inhibitor TVB-2640 (HY112829, MCE, USA) (100 mg/kg) once daily by oral gavage for 3 consecutive weeks. .. Measure tumor growth every six days with a digital caliper.

    Staining:

    Article Title: Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma
    Article Snippet: In vivo trials of TVB-2640 treatment, a total of 5 × 10 6 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice.In vivo trials of TVB-2640 treatment, a total of 5 × 10 6 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice.. Four days after inoculation, the mice were randomly divided into two groups and treated with either the vehicle (30 % PEG400) or the FASN inhibitor TVB-2640 (HY-112829, MCE, USA) (100 mg/kg) once daily by oral gavage for 3 consecutive weeks.. Measure tumor growth every six days with a digital caliper.Measure tumor growth every six days with a digital caliper.

    Article Title: Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma.
    Article Snippet: vivo trials of TVB-2640 treatment, a total of 5 × 106 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice. .. Four days after inoculation, the mice were randomly divided into two groups and treated with either the vehicle (30 % PEG400) or the FASN inhibitor TVB-2640 (HY112829, MCE, USA) (100 mg/kg) once daily by oral gavage for 3 consecutive weeks. .. Measure tumor growth every six days with a digital caliper.

    Knockdown:

    Article Title: Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma
    Article Snippet: In vivo trials of TVB-2640 treatment, a total of 5 × 10 6 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice.In vivo trials of TVB-2640 treatment, a total of 5 × 10 6 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice.. Four days after inoculation, the mice were randomly divided into two groups and treated with either the vehicle (30 % PEG400) or the FASN inhibitor TVB-2640 (HY-112829, MCE, USA) (100 mg/kg) once daily by oral gavage for 3 consecutive weeks.. Measure tumor growth every six days with a digital caliper.Measure tumor growth every six days with a digital caliper.

    Article Title: Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma.
    Article Snippet: vivo trials of TVB-2640 treatment, a total of 5 × 106 786O cells with KAT2B knockdown were subcutaneously injected into a 4-week-old nude mice. .. Four days after inoculation, the mice were randomly divided into two groups and treated with either the vehicle (30 % PEG400) or the FASN inhibitor TVB-2640 (HY112829, MCE, USA) (100 mg/kg) once daily by oral gavage for 3 consecutive weeks. .. Measure tumor growth every six days with a digital caliper.



    Similar Products

    fasn inhibitor tvb 2640  (MedChemExpress)
    94
    MedChemExpress fasn inhibitor tvb 2640
    Therapeutic targeting of KAT2B-low RCC with a FASN inhibitor (A-B) Representative images of IHC staining of FASN in RCC cohort and statistical analysis. (C) Representative images of IHC staining for FASN and KAT2B in RCC tissues with high and low KAT2B expression. (D) Scatter plot of the relationship among KAT2B expression and FASN expression in advanced RCC tumors (n = 53). (E) The cell viability of ACHN and Caki-1 cells after treated <t>with</t> <t>TVB-2640</t> (n = 4). (F) The cell viability of 786O and 769P cells after treated with TVB-2640 (n = 10). Proteins from three independent sites in RCC tissues were extracted to detect KAT2B expression. (H) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM). 15 organoids were randomly selected from each group for statistical analysis. (I) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM) (n = 15). (J) Representative images of two PDOs with different KAT2B expression after treatment with TVB-2640 (n = 10). (K) Representative images of PRO-1 staining of PDOs. (L-M) The cell viability of ACHN cells (L) and case 1 primary RCC cells (M) with KAT2B knockdown after treated with TVB-2640 (n = 4). (N-O) The picture (N) of xenograft using 786O cells with KAT2B knockdown after treated with TVB-2640, and tumor growth curve (n = 4). Data were analyzed by unpaired t test (B, H, I, J), one-way ANOVA (O) or two-way ANOVA (E, F, G, L, M).
    Fasn Inhibitor Tvb 2640, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fasn+inhibitor+tvb+2640/Denifanstat/pmc13131402-129-23-27
    Average 94 stars, based on 1 article reviews
    fasn inhibitor tvb 2640 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    fas fasn inhibitor tvb 2640  (Selleck Chemicals)
    93
    Selleck Chemicals fas fasn inhibitor tvb 2640
    Therapeutic targeting of KAT2B-low RCC with a FASN inhibitor (A-B) Representative images of IHC staining of FASN in RCC cohort and statistical analysis. (C) Representative images of IHC staining for FASN and KAT2B in RCC tissues with high and low KAT2B expression. (D) Scatter plot of the relationship among KAT2B expression and FASN expression in advanced RCC tumors (n = 53). (E) The cell viability of ACHN and Caki-1 cells after treated <t>with</t> <t>TVB-2640</t> (n = 4). (F) The cell viability of 786O and 769P cells after treated with TVB-2640 (n = 10). Proteins from three independent sites in RCC tissues were extracted to detect KAT2B expression. (H) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM). 15 organoids were randomly selected from each group for statistical analysis. (I) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM) (n = 15). (J) Representative images of two PDOs with different KAT2B expression after treatment with TVB-2640 (n = 10). (K) Representative images of PRO-1 staining of PDOs. (L-M) The cell viability of ACHN cells (L) and case 1 primary RCC cells (M) with KAT2B knockdown after treated with TVB-2640 (n = 4). (N-O) The picture (N) of xenograft using 786O cells with KAT2B knockdown after treated with TVB-2640, and tumor growth curve (n = 4). Data were analyzed by unpaired t test (B, H, I, J), one-way ANOVA (O) or two-way ANOVA (E, F, G, L, M).
    Fas Fasn Inhibitor Tvb 2640, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fasn+inhibitor+tvb+2640/TVB-2640/pmc08539835-181-22-25
    Average 93 stars, based on 1 article reviews
    fas fasn inhibitor tvb 2640 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    tvb-2640, a fasn inhibitor  (3-V Biosciences)
    90
    3-V Biosciences tvb-2640, a fasn inhibitor
    Therapeutic targeting of KAT2B-low RCC with a FASN inhibitor (A-B) Representative images of IHC staining of FASN in RCC cohort and statistical analysis. (C) Representative images of IHC staining for FASN and KAT2B in RCC tissues with high and low KAT2B expression. (D) Scatter plot of the relationship among KAT2B expression and FASN expression in advanced RCC tumors (n = 53). (E) The cell viability of ACHN and Caki-1 cells after treated <t>with</t> <t>TVB-2640</t> (n = 4). (F) The cell viability of 786O and 769P cells after treated with TVB-2640 (n = 10). Proteins from three independent sites in RCC tissues were extracted to detect KAT2B expression. (H) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM). 15 organoids were randomly selected from each group for statistical analysis. (I) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM) (n = 15). (J) Representative images of two PDOs with different KAT2B expression after treatment with TVB-2640 (n = 10). (K) Representative images of PRO-1 staining of PDOs. (L-M) The cell viability of ACHN cells (L) and case 1 primary RCC cells (M) with KAT2B knockdown after treated with TVB-2640 (n = 4). (N-O) The picture (N) of xenograft using 786O cells with KAT2B knockdown after treated with TVB-2640, and tumor growth curve (n = 4). Data were analyzed by unpaired t test (B, H, I, J), one-way ANOVA (O) or two-way ANOVA (E, F, G, L, M).
    Tvb 2640, A Fasn Inhibitor, supplied by 3-V Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fasn+inhibitor+tvb+2640/tvb+3166/pm29447918-109-6-13
    Average 90 stars, based on 1 article reviews
    tvb-2640, a fasn inhibitor - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    fatty acid synthase (fasn) inhibitor tvb-2640  (Schmid GmbH)
    90
    Schmid GmbH fatty acid synthase (fasn) inhibitor tvb-2640
    Therapeutic targeting of KAT2B-low RCC with a FASN inhibitor (A-B) Representative images of IHC staining of FASN in RCC cohort and statistical analysis. (C) Representative images of IHC staining for FASN and KAT2B in RCC tissues with high and low KAT2B expression. (D) Scatter plot of the relationship among KAT2B expression and FASN expression in advanced RCC tumors (n = 53). (E) The cell viability of ACHN and Caki-1 cells after treated <t>with</t> <t>TVB-2640</t> (n = 4). (F) The cell viability of 786O and 769P cells after treated with TVB-2640 (n = 10). Proteins from three independent sites in RCC tissues were extracted to detect KAT2B expression. (H) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM). 15 organoids were randomly selected from each group for statistical analysis. (I) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM) (n = 15). (J) Representative images of two PDOs with different KAT2B expression after treatment with TVB-2640 (n = 10). (K) Representative images of PRO-1 staining of PDOs. (L-M) The cell viability of ACHN cells (L) and case 1 primary RCC cells (M) with KAT2B knockdown after treated with TVB-2640 (n = 4). (N-O) The picture (N) of xenograft using 786O cells with KAT2B knockdown after treated with TVB-2640, and tumor growth curve (n = 4). Data were analyzed by unpaired t test (B, H, I, J), one-way ANOVA (O) or two-way ANOVA (E, F, G, L, M).
    Fatty Acid Synthase (Fasn) Inhibitor Tvb 2640, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fasn+inhibitor+tvb+2640/fatty+acid+synthase++fasn++inhibitor+tvb+2640/pm28922023-709-48-18
    Average 90 stars, based on 1 article reviews
    fatty acid synthase (fasn) inhibitor tvb-2640 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Therapeutic targeting of KAT2B-low RCC with a FASN inhibitor (A-B) Representative images of IHC staining of FASN in RCC cohort and statistical analysis. (C) Representative images of IHC staining for FASN and KAT2B in RCC tissues with high and low KAT2B expression. (D) Scatter plot of the relationship among KAT2B expression and FASN expression in advanced RCC tumors (n = 53). (E) The cell viability of ACHN and Caki-1 cells after treated with TVB-2640 (n = 4). (F) The cell viability of 786O and 769P cells after treated with TVB-2640 (n = 10). Proteins from three independent sites in RCC tissues were extracted to detect KAT2B expression. (H) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM). 15 organoids were randomly selected from each group for statistical analysis. (I) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM) (n = 15). (J) Representative images of two PDOs with different KAT2B expression after treatment with TVB-2640 (n = 10). (K) Representative images of PRO-1 staining of PDOs. (L-M) The cell viability of ACHN cells (L) and case 1 primary RCC cells (M) with KAT2B knockdown after treated with TVB-2640 (n = 4). (N-O) The picture (N) of xenograft using 786O cells with KAT2B knockdown after treated with TVB-2640, and tumor growth curve (n = 4). Data were analyzed by unpaired t test (B, H, I, J), one-way ANOVA (O) or two-way ANOVA (E, F, G, L, M).

    Journal: Journal of Advanced Research

    Article Title: Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma

    doi: 10.1016/j.jare.2025.08.007

    Figure Lengend Snippet: Therapeutic targeting of KAT2B-low RCC with a FASN inhibitor (A-B) Representative images of IHC staining of FASN in RCC cohort and statistical analysis. (C) Representative images of IHC staining for FASN and KAT2B in RCC tissues with high and low KAT2B expression. (D) Scatter plot of the relationship among KAT2B expression and FASN expression in advanced RCC tumors (n = 53). (E) The cell viability of ACHN and Caki-1 cells after treated with TVB-2640 (n = 4). (F) The cell viability of 786O and 769P cells after treated with TVB-2640 (n = 10). Proteins from three independent sites in RCC tissues were extracted to detect KAT2B expression. (H) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM). 15 organoids were randomly selected from each group for statistical analysis. (I) Representative images of Caki-1 and ACHN organoids after treatment with TVB-2640 (7.5 μM) (n = 15). (J) Representative images of two PDOs with different KAT2B expression after treatment with TVB-2640 (n = 10). (K) Representative images of PRO-1 staining of PDOs. (L-M) The cell viability of ACHN cells (L) and case 1 primary RCC cells (M) with KAT2B knockdown after treated with TVB-2640 (n = 4). (N-O) The picture (N) of xenograft using 786O cells with KAT2B knockdown after treated with TVB-2640, and tumor growth curve (n = 4). Data were analyzed by unpaired t test (B, H, I, J), one-way ANOVA (O) or two-way ANOVA (E, F, G, L, M).

    Article Snippet: Four days after inoculation, the mice were randomly divided into two groups and treated with either the vehicle (30 % PEG400) or the FASN inhibitor TVB-2640 (HY-112829, MCE, USA) (100 mg/kg) once daily by oral gavage for 3 consecutive weeks.

    Techniques: Immunohistochemistry, Expressing, Staining, Knockdown